var data={"title":"Clopidogrel: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Clopidogrel: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5930?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=clopidogrel-drug-information\" class=\"drug drug_general\">see &quot;Clopidogrel: Drug information&quot;</a> and <a href=\"topic.htm?path=clopidogrel-patient-drug-information\" class=\"drug drug_patient\">see &quot;Clopidogrel: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10072956\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Diminished antiplatelet effect in patients with two loss-of-function alleles of the CYP2C19 gene:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">The effectiveness of clopidogrel results from its antiplatelet activity, which is dependent on its conversion to an active metabolite by the cytochrome P450 (CYP-450) system, principally CYP2C19. Clopidogrel at recommended doses forms less of the active metabolite and has a reduced effect on platelet activity in patients who are homozygous for nonfunctional alleles of the CYP2C19 genes (termed &ldquo;CYP2C19 poor metabolizers&rdquo;). Tests are available to identify patients who are CYP2C19 poor metabolizers. Consider use of another platelet P2Y12 inhibitor in patients identified as CYP2C19 poor metabolizers.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153626\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Plavix</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50667916\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Plavix</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1006665\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antiplatelet Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11442270\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Antiplatelet effect:</b> Limited data available: Oral: 0.2 mg/kg/dose once daily. A double-blind, placebo-controlled trial of 906 patients (n=461 neonates; n=445 infants &le;3 months) with cyanotic congenital heart disease surgically treated with a systemic-to-pulmonary artery shunt did not demonstrate a clinical benefit compared to placebo. Concomitant aspirin was used in 88% of patients (NCT00396877, 2011). In another trial, 0.2 mg/kg/dose once daily was found to achieve a mean inhibition of platelet aggregation similar to a standard adult dose; <b>Note:</b> This study (PICOLO Trial) included 73 evaluable patients [n=34 neonates (with exclusion of patients with weight &lt;2 kg and GA &lt;35 weeks); n=39 infants &le;24 months] with a systemic-to-pulmonary artery shunt, intracardiac or intravascular stent, Kawasaki disease, or arterial graft; 79% of patients received concomitant aspirin (Li 2008).  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1006697\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=clopidogrel-drug-information\" class=\"drug drug_general\">see &quot;Clopidogrel: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Antiplatelet effect:</b> Limited data available: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children &le;24 months: In the PICOLO trial, a dose of 0.2 mg/kg/dose once daily was found to achieve a mean inhibition of platelet aggregation similar to adults receiving the recommended dose; <b>Note:</b> This study included pediatric patients with a systemic-to-pulmonary artery shunt, intracardiac or intravascular stent, Kawasaki disease, or arterial graft; 79% of patients received concomitant aspirin (Li  2008).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &gt;2 years and Adolescents: Initial dose: 1 mg/kg once daily; titrate to response; in general, do not exceed adult dose (Finkelstein 2005; Soman 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Recent MI, recent stroke, or established peripheral arterial disease:</b> 75 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute coronary syndrome:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Unstable angina, non-ST-segment elevation myocardial infarction (UA/NSTEMI): Initial: 300 mg loading dose, followed by 75 mg once daily for at least 1 month and ideally up to 12 months (in combination with aspirin 75 to 162 mg once daily indefinitely) (Wright 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ST-segment elevation acute myocardial infarction (STEMI): 75 mg once daily (in combination with aspirin 162 to 325 mg initially, followed by 81 to 162 mg/day); <b>Note:</b> The CLARITY-TIMI 28 study used a 300 mg loading dose of clopidogrel (with thrombolysis) demonstrating an improvement in the patency rate of the infarct-related artery and reduction in ischemic complications. The duration of therapy was &lt;28 days (usually until hospital discharge) unless nonprimary percutaneous coronary intervention (PCI) was performed (Sabatine 2005).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">The  American College of Chest Physicians recommends (Goodman 2008):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Patients &le;75 years: Initial: 300 mg loading dose, followed by 75 mg once daily for up to 28 days (in combination with aspirin)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Patients &gt;75 years: 75 mg once daily for up to 28 days (with or without thrombolysis)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Percutaneous coronary intervention (PCI) for UA/NSTEMI or STEMI:</b> Loading dose: 300 to 600 mg (600 mg may be preferred for early invasive strategy with UA/NSTEMI) given as early as possible before or at the time of PCI followed by 75 mg once daily. <b>Note:</b> If an initial loading dose of 300 mg was given prior to PCI, a supplemental loading dose of 300 mg (total loading dose: 600 mg) may be administered (Kushner 2009). For patients with UA/NSTEMI, it has been recommended that the loading dose be given at least 2 hours (or 24 hours in patients unable to take aspirin) prior to PCI (<i>Chest</i> 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Higher vs standard maintenance dosing: May consider a maintenance dose of 150 mg once daily for 6 days, then 75 mg once daily thereafter in patients not at high risk for bleeding (CURRENT-OASIS 7 Investigators 2010; Wright 2011); however, in another study, in patients with high on-treatment platelet reactivity, the use of 150 mg once daily for 6 months did not demonstrate a difference in 6-month incidence of death from cardiovascular causes, nonfatal MI, or stent thrombosis compared to standard dose therapy (Price 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Duration of clopidogrel (in combination with aspirin) after stent placement: <b>Premature interruption of therapy may result in stent thrombosis with subsequent fatal and nonfatal MI.</b> With STEMI, clopidogrel for at least 12 months regardless of stent type (ie, either bare metal or drug eluting stent) is recommended (Kushner, 2009). With UA/NSTEMI, at least 12 months of clopidogrel is recommended in patients receiving a drug eluting stent (DES) unless the risk of bleeding outweighs the benefits. For bare metal stent (BMS) placement, at least 1 month and ideally up to 12 months duration is recommended unless the risk of bleeding outweighs the benefits; then, a minimum of 2 weeks is recommended (Wright, 2011). In either setting, a duration &gt;15 months may be considered in patients with DES placement (Kushner 2009; Wright 2011). For patients without ongoing ACS, clopidogrel should be continued for at least 1 month (for BMS) or at least 12 months (for DES) (Becker 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>CYP2C19 poor metabolizers (ie, CYP2C19*2 or *3 carriers):</b> Although routine genetic testing is not recommended in patients treated with clopidogrel undergoing PCI, testing may be considered to identify poor metabolizers who would be at risk for poor outcomes while receiving clopidogrel; if identified, these patients may be considered for an alternative P2Y12 inhibitor (Levine 2011). An appropriate regimen for this patient population has not been established in clinical outcome trials. Although the manufacturer suggests a 600 mg loading dose, followed by 150 mg once daily, it does not appear that this dosing strategy improves outcomes for this patient population (Price 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> No dosage adjustment is required; use with caution; experience is limited; <b>Note:</b> Plasma concentrations of the main circulating metabolite were lower in adult patients with CrCl 5 to 15 mL/minute versus patients with CrCl 30 to 60 mL/minute or healthy adults. Inhibition of ADP-induced platelet aggregation was 25% lower compared to healthy adults; however, prolongation of bleeding time was similar.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Use with caution; experience is limited; <b>Note:</b> Inhibition of ADP-induced platelet aggregation and mean bleeding time prolongation were similar in adult patients with severe hepatic impairment compared to healthy subjects after repeated doses of 75 mg once daily for 10 days.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153606\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Plavix: 75 mg, 300 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 75 mg, 300 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153591\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11566548\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM243349.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+Btau8Jzc5BLV85NUiGV682FCKj3jdzG6SYXt3mbNdAw==&amp;TOPIC_ID=12984\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM243349.pdf</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6074607\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">May be administered without regard to food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153622\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1006666\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Reduction of atherothrombotic events (MI, stroke, and vascular deaths) in patients with recent MI, stroke, or established peripheral arterial disease (FDA approved in adults); reduction of atherothrombotic events in patients with non-ST-segment elevation acute coronary syndrome (unstable angina and non-Q-wave MI) managed medically and through percutaneous coronary intervention (with or without stent) or CABG (FDA approved in adults); reduction of death rate and atherothrombotic events in patients with ST-segment elevation acute MI (STEMI) managed medically (FDA approved in adults).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153666\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Plavix may be confused with Elavil, Paxil, Pradax (Canada), Pradaxa</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153664\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">As with all drugs that may affect hemostasis, bleeding is associated with clopidogrel. Hemorrhage may occur at virtually any site. Risk is dependent on multiple variables, including the concurrent use of multiple agents that alter hemostasis and patient susceptibility.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Gastrointestinal hemorrhage</p>\n    <p style=\"text-indent:-4em;margin-left:4em;\">Hematologic &amp; oncologic: Hematoma, major hemorrhage, minor hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Epistaxis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Abnormal hepatic function tests, acute generalized exanthematous pustulosis, acute hepatic failure, ageusia, agranulocytosis, anaphylactoid reaction, angioedema, aplastic anemia, arthralgia, arthritis, bronchospasm, bullous rash, colitis (including ulcerative or lymphocytic), confusion, diarrhea, DRESS syndrome, drug-induced hypersensitivity, duodenal ulcer, eczema, eosinophilic pneumonitis, erythema multiforme, erythematous rash, exfoliative dermatitis, fever, gastric ulcer, hallucination, headache, hemophilia A (acquired), hepatitis (noninfectious), hypersensitivity reaction, hypotension, increased serum creatinine, interstitial pneumonitis, intracranial hemorrhage, lichen planus, maculopapular rash, myalgia, pancreatitis, pancytopenia, pruritus, serum sickness, Stevens-Johnson syndrome, stomatitis, taste disorder, thrombotic thrombocytopenic purpura, toxic epidermal necrolysis, urticaria, vasculitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153611\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity (eg, anaphylaxis) to clopidogrel or any component of the formulation; active pathological bleeding (eg, peptic ulcer, intracranial hemorrhage).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Significant liver impairment or cholestatic jaundice; concomitant use of repaglinide.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153595\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding: Clopidogrel increases the risk of bleeding. Use is contraindicated in patients with active pathological bleeding (eg, peptic ulcer, intracranial hemorrhage). Additional risk factors for bleeding include age &ge;75 years, propensity to bleed (eg, recent trauma or surgery, recent or recurrent GI bleeding, active peptic ulcer disease, severe hepatic impairment), body weight &lt;60 kg, CABG or other surgical procedure, concomitant use of medications that increase risk of bleeding (eg, warfarin, NSAIDs). Use with caution in patients with platelet disorders, bleeding disorders and/or at increased risk for bleeding. Bleeding should be suspected if patient becomes hypotensive after undergoing recent coronary angiography, PCI, CABG, or other surgical procedure even if overt signs of bleeding do not exist. It may be possible to restore hemostasis by administering exogenous platelets; however, platelet transfusions within 4 hours of the loading dose or 2 hours of the maintenance dose may be less effective.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thienopyridine hypersensitivity: Because of structural similarities, cross-reactivity has been reported among the thienopyridines (clopidogrel, prasugrel, and ticlopidine); use with caution or avoid in patients with hypersensitivity or hematologic reactions to previous thienopyridine use. Use of clopidogrel is contraindicated in patients with hypersensitivity to clopidogrel. Although desensitization may be considered for mild-to-moderate hypersensitivity, do not desensitize patients with prior life-threatening allergic reactions to clopidogrel (eg, toxic epidermal necrolysis, exfoliative dermatitis, Stevens-Johnson syndrome, TTP) (Lokhandwala 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thrombotic thrombocytopenic purpura (TTP): Cases of TTP (usually occurring within the first 2 weeks of therapy), resulting in some fatalities, have been reported; urgent plasmapheresis is required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lacunar stroke: In patients with recent lacunar stroke (within 180 days), the use of clopidogrel in addition to aspirin did not significantly reduce the incidence of the primary outcome of stroke recurrence (any ischemic stroke or intracranial hemorrhage) compared to aspirin alone; the use of clopidogrel in addition to aspirin did however increase the risk of major hemorrhage and the rate of all-cause mortality (SPS3 Investigators, 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with moderate to severe renal impairment (experience is limited).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CYP2C19 poor metabolizers: <b>[US Boxed Warning]: </b><b>Effectiveness of clopidogrel results from its antiplatelet activity, which is dependent on its conversion to an active metabolite by the CYP-450 system, principally CYP2C19. In patients who are homozygous for nonfunctional alleles of the CYP2C19 genes (termed &ldquo;CYP2C19 poor metabolizers&rdquo;), clopidogrel at recommended doses forms less of the active metabolite and has a reduced effect on platelet activity. Tests are available to identify patients who are CYP2C19 poor metabolizers. Consider use of another platelet P2Y12 inhibitor in patients identified as CYP2C19 poor metabolizers. </b>Genetic testing may be considered prior to initiating clopidogrel in patients at moderate or high risk for poor outcomes (eg, PCI in patients with extensive and/or very complex disease). The optimal dose for CYP2C19 poor metabolizers has yet to be determined. After initiation of clopidogrel, functional testing (eg, VerifyNow&reg; P2Y12 assay) may also be done to determine clopidogrel responsiveness (Holmes, 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lower GI bleed patients: An individualized and multidisciplinary approach should be utilized to determine therapy discontinuation and management in patients with acute lower GI bleed (LGIB) who are on antiplatelet medications; risk of ongoing bleeding should be weighed with risk of thromboembolic events. In patients receiving dual antiplatelet therapy (aspirin plus P2Y<sub>12 </sub>receptor blocker [eg, clopidogrel, prasugrel, ticagrelor, ticlopidine]) or thienopyridine monotherapy, the thienopyridine should generally be resumed as soon as possible and at least within 7 days, taking into account control of bleeding and cardiovascular risk (aspirin should <i>not</i> be discontinued); however, dual antiplatelet therapy should <i>not </i>be discontinued in the 90 days post-acute coronary syndrome or 30 days post-coronary stenting (Strate 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgical patients: In patients undergoing elective surgery, consider discontinuing 5 days before surgery (except in patients with cardiac stents that have not completed their full course of dual antiplatelet therapy; patient-specific situations need to be discussed with cardiologist; AHA/ACC/SCAI/ACS/ADA Science Advisory provides recommendations) (Grines 2007). Elective noncardiac surgery should not be performed in patients in whom dual antiplatelet therapy (DAPT) will need to be discontinued perioperatively within 30 days following bare metal stent (BMS) placement or within 12 months after drug-eluting stent (DES) placement. In patients undergoing urgent non-cardiac surgery during the first 4 to 6 weeks after BMS or DES placement, continue DAPT. In patients with stents undergoing surgery that requires discontinuation of the P2Y<sub>12</sub> inhibitor (eg, clopidogrel), continue aspirin and re-start the P2Y<sub>12</sub> inhibitor as soon as possible after surgery (ACC/AHA [Fleisher 2014]). In patients undergoing elective CABG, discontinue clopidogrel at least 5 days before procedure; when urgent CABG is necessary, the ACCF/AHA CABG guidelines recommend discontinuation for at least 24 hours prior to surgery (ACCF/AHA [Hillis 2011]). The ACCF/AHA STEMI guidelines recommend discontinuation for at least 24 hours prior to <i>on-pump</i> CABG if possible; <i>off-pump</i> CABG may be performed within 24 hours of clopidogrel administration if the benefits of prompt revascularization outweigh the risks of bleeding (ACCF/AHA [O'Gara 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Coronary artery stents: Premature interruption of therapy may result in stent thrombosis with subsequent fatal and nonfatal MI. Duration of therapy, in general, is determined by the type of stent placed (bare metal or drug eluting) and whether an ACS event was ongoing at the time of placement (ACC/AHA [Levine 2016]; AHA/ACC/SCAI/ACS/ADA [Grines 2007]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153651\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2C19 (major), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2B6 (weak), CYP2C8 (moderate), CYP2C9 (weak), OATP1B1/SLCO1B1</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153600\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12984&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the antiplatelet effect of other Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amiodarone: May decrease serum concentrations of the active metabolite(s) of Clopidogrel.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amodiaquine: CYP2C8 Inhibitors (Moderate) may increase the serum concentration of Amodiaquine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apixaban: Antiplatelet Agents (P2Y12 Inhibitors) may enhance the adverse/toxic effect of Apixaban. Specifically, the risk for bleeding may be increased.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: CYP2B6 Inhibitors (Weak) may increase the serum concentration of BuPROPion. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers: May diminish the therapeutic effect of Clopidogrel.<b> Exceptions: </b>Clevidipine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cangrelor: May diminish the antiplatelet effect of Clopidogrel. More specifically, while the use of Cangrelor is expected to increase total platelet inhibition in patients who have previously received Clopidogrel, Cangrelor is expected to decrease binding of Clopidogrel metabolites to P2Y12 receptors and thus reduce the extent of irreversible platelet inhibition. Management: Avoid administration of clopidogrel until cangrelor infusion is discontinued.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalothin: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Cephalothin. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C19 Inducers (Strong): May increase serum concentrations of the active metabolite(s) of Clopidogrel.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C19 Inhibitors (Moderate): May decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Due to a risk for impaired clopidogrel effectiveness with such a combination, carefully consider the need for a moderate CYP2C19 inhibitor in patients receiving clopidogrel. Monitor patients closely for evidence of a diminished response to clopidogrel.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C19 Inhibitors (Strong): May decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Due to a risk for impaired clopidogrel effectiveness with such a combination, carefully consider the need for a strong CYP2C19 inhibitor in patients receiving clopidogrel. Monitor patients closely for evidence of a diminished response to clopidogrel.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C8 Substrates (High risk with Inhibitors): CYP2C8 Inhibitors (Moderate) may decrease the metabolism of CYP2C8 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: Antiplatelet Agents (P2Y12 Inhibitors) may enhance the adverse/toxic effect of Dabigatran Etexilate. Specifically, the risk of bleeding may be increased. Antiplatelet Agents (P2Y12 Inhibitors) may increase the serum concentration of Dabigatran Etexilate. Specifically, clopidogrel may increase dabigatran serum concentrations.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deoxycholic Acid: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexlansoprazole: May decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Due to the possible risk for impaired clopidogrel effectiveness, clinicians should carefully consider the need for proton pump inhibitor therapy in patients receiving clopidogrel.  Other acid-lowering therapies do not appear to share this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edoxaban: Antiplatelet Agents (P2Y12 Inhibitors) may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased.  Management: Carefully consider the anticipated risks and benefits of this combination. If combined, increased monitoring for bleeding is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Erythromycin (Systemic): May diminish the antiplatelet effect of Clopidogrel.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Esomeprazole: May diminish the antiplatelet effect of Clopidogrel. Esomeprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Clopidogrel prescribing information recommends avoiding concurrent use with esomeprazole. Rabeprazole or pantoprazole may be lower-risk alternatives to esomeprazole.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FentaNYL: May diminish the antiplatelet effect of Antiplatelet Agents (P2Y12 Inhibitors). FentaNYL may decrease the serum concentration of Antiplatelet Agents (P2Y12 Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FluvoxaMINE: May enhance the adverse/toxic effect of Clopidogrel. Specifically, the risk for bleeding may be increased. FluvoxaMINE may decrease serum concentrations of the active metabolite(s) of Clopidogrel.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grapefruit Juice: May decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Advise patients receiving clopidogrel to minimize consumption of grapefruit and grapefruit juice.  Consumption of three 200 mL glasses of grapefruit juice a day may substantially reduce clopidogrel antiplatelet effects.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibritumomab Tiuxetan: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lansoprazole: May decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Due to the possible risk for impaired clopidogrel effectiveness, clinicians should carefully consider the need for proton pump inhibitor therapy in patients receiving clopidogrel.  Other acid-lowering therapies do not appear to share this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limaprost: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Morphine (Liposomal): May diminish the antiplatelet effect of Antiplatelet Agents (P2Y12 Inhibitors). Morphine (Liposomal) may decrease the serum concentration of Antiplatelet Agents (P2Y12 Inhibitors). Management: Consider alternative anti-ischemic/analgesic therapies (eg, beta-blockers, nitroglycerin) in patients with acute coronary syndromes treated with a P2Y12 inhibitor when possible. The risks associated with other opioids are unknown.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Morphine (Systemic): May diminish the antiplatelet effect of Antiplatelet Agents (P2Y12 Inhibitors). Morphine (Systemic) may decrease the serum concentration of Antiplatelet Agents (P2Y12 Inhibitors). Management: Consider alternative anti-ischemic/analgesic therapies (eg, beta-blockers, nitroglycerin) in patients with acute coronary syndromes treated with a P2Y12 inhibitor when possible. The risks associated with other opioids are unknown.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omeprazole: May diminish the antiplatelet effect of Clopidogrel. Omeprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Clopidogrel labeling recommends avoiding concurrent omeprazole due to a possible decrease in clopidogrel effectiveness. Rabeprazole or pantoprazole may be lower-risk alternatives to omeprazole.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PACLitaxel (Conventional): Clopidogrel may increase the serum concentration of PACLitaxel (Conventional). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PACLitaxel (Protein Bound): Clopidogrel may increase the serum concentration of PACLitaxel (Protein Bound). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pantoprazole: May decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Due to the possible risk for impaired clopidogrel effectiveness, clinicians should carefully consider the need for proton pump inhibitor therapy in patients receiving clopidogrel.  Other acid-lowering therapies do not appear to share this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pioglitazone: Clopidogrel may increase the serum concentration of Pioglitazone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RABEprazole: May decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Due to the possible risk for impaired clopidogrel effectiveness, clinicians should carefully consider the need for proton pump inhibitor therapy in patients receiving clopidogrel.  Other acid-lowering therapies do not appear to share this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Repaglinide: Clopidogrel may increase the serum concentration of Repaglinide.  Management: Avoid use of clopidogrel and repaglinide if possible; if the combination must be used, limit total repaglinide daily dose to no more than 4 mg. This is contraindicated in some non-US labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rivaroxaban: Antiplatelet Agents (P2Y12 Inhibitors) may enhance the adverse/toxic effect of Rivaroxaban. Specifically, the risk of bleeding may be increased.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rosuvastatin: Clopidogrel may increase the serum concentration of Rosuvastatin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selexipag: CYP2C8 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Selexipag. CYP2C8 Inhibitors (Moderate) may increase the serum concentration of Selexipag.  Management: If initiating selexipag in a patient on a moderate CYP2C8 inhibitor, consider a less frequent dosing regimen (ie, once daily). If initiating a moderate CYP2C8 inhibitor in a patient on selexipag, consider a selexipag dose reduction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urokinase: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin E (Systemic): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Warfarin: Clopidogrel may enhance the anticoagulant effect of Warfarin. <i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153623\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Consumption of three 200 mL glasses of grapefruit juice a day may substantially reduce clopidogrel antiplatelet effects. Management: Avoid or minimize the consumption of grapefruit or grapefruit juice (Holmberg, 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153602\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3343717\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Information related to use during pregnancy is limited (Bauer 2012; DeSantis 2011; Myers 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1006703\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Signs of bleeding; hemoglobin and hematocrit periodically. Monitor mean inhibition of platelet aggregation: Goal of 30% to 50% inhibition (similar to adults receiving 75 mg/day). For unstable angina/non-ST-elevation MI in adults, platelet function testing has been used to determine platelet inhibitory response if results of testing may alter management (Wright, 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153594\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Clopidogrel requires <i>in vivo</i> biotransformation to an active thiol metabolite. The active metabolite irreversibly blocks the P2Y<sub>12</sub> component of ADP receptors on the platelet surface, which prevents activation of the GPIIb/IIIa receptor complex, thereby reducing platelet aggregation. Platelets blocked by clopidogrel are affected for the remainder of their lifespan (~7-10 days).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153610\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Inhibition of platelet aggregation (IPA): Dose-dependent:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300-600 mg loading dose: Detected within 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50-100 mg/day: Detected by the second day of treatment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Peak effect: Time to maximal IPA: Dose-dependent: <b>Note:</b> Degree of IPA based on adenosine diphosphate (ADP) concentration used during light aggregometry:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300-600 mg loading dose:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">ADP 5 micromole/L: 20% to 30% IPA at 6 hours post administration (Montelescot, 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">ADP 20 micromole/L: 30% to 37% IPA at 6 hours post administration (Montelescot, 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50-100 mg/day: ADP 5 micromole/L: 50% to 60% IPA at 5-7 days (Herbert, 1993) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration of action: Platelet aggregation and bleeding time gradually return to baseline after ~5 days after discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Rapid, well absorbed </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: Parent drug: 98%; Inactive metabolite (carboxylic acid derivative): 94%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Extensively hepatic via esterase-mediated hydrolysis to a carboxylic acid derivative (inactive) and via CYP450-mediated (CYP2C19 primarily) oxidation to a thiol metabolite (active) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Parent drug: ~6 hours; Thiol derivative (active metabolite): ~30 minutes; carboxylic acid derivative (inactive; main circulating metabolite): ~8 hours; <b>Note:</b> A clopidogrel radiolabeled study has shown that covalent binding to platelets accounts for 2% of radiolabel and has a half-life of 11 days.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: ~0.75 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Following administration of a single <sup>14</sup>C-labeled clopidogrel oral dose; radioactivity measured over 5 days: Urine (50%); feces (46%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10806355\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">A 5 mg/mL oral suspension may be made using tablets. Crush four 75 mg tablets and reduce to a fine powder. Add a small amount of a 1:1 mixture of Ora-Sweet&reg; and Ora-Plus&reg; and mix to a uniform paste; mix while adding the vehicle in geometric proportions to <b>almost</b> 60 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 60 mL. Label &quot;shake well&quot;. Stable 60 days at room temperature or under refrigeration.</p>\n    <div class=\"reference\">Skillman KL, Caruthers RL, and Johnson CE, &quot;Stability of an Extemporaneously Prepared Clopidogrel Oral Suspension,&quot; <i>Am J Health Syst Pharm</i>, 2010, 67(7):559-61.<span class=\"pubmed-id\">20237383</span></div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153613\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Clopidogrel Bisulfate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg (90): $625.72</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (30): $762.70</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Plavix Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg (90): $696.11</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (30): $928.13</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153615\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aclop (AT);</li>\n      <li>Actaclo (PH);</li>\n      <li>Agrelan (ES);</li>\n      <li>Antiplar (PH);</li>\n      <li>Antiplatt (ET);</li>\n      <li>Apolets (TH);</li>\n      <li>Arapamin (ES);</li>\n      <li>Artepid (ID);</li>\n      <li>Artheogrel (PH);</li>\n      <li>Ateplax (EC, PE);</li>\n      <li>Bidogrel (ZW);</li>\n      <li>Bilgrel (VN);</li>\n      <li>Caplor (VN);</li>\n      <li>Ceranade (KR);</li>\n      <li>Ceruvin (TH);</li>\n      <li>Clavix (MY);</li>\n      <li>Clentel (EC);</li>\n      <li>Clidorel (ID);</li>\n      <li>Clo V (KR);</li>\n      <li>Cloart (KR);</li>\n      <li>Clodel (IE);</li>\n      <li>Clodor (LB);</li>\n      <li>Clofix (TW);</li>\n      <li>Clogin (ID);</li>\n      <li>Clogrel (BD);</li>\n      <li>Clood (IL);</li>\n      <li>Clopacin (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Clopex (QA);</li>\n      <li>Clopid (SY);</li>\n      <li>Clopidexcel (IL);</li>\n      <li>Clopidolut (VN);</li>\n      <li>Clopidrol (PH);</li>\n      <li>Clopilet (IN);</li>\n      <li>Clopimed (LK);</li>\n      <li>Clopimet (PH);</li>\n      <li>Clopiright (HK);</li>\n      <li>Clopistad (HK);</li>\n      <li>Clopitab (LK);</li>\n      <li>Clopivas (HK);</li>\n      <li>Clopivaz (PH);</li>\n      <li>Clopivid (HK, MY);</li>\n      <li>Cloprez (LK);</li>\n      <li>Clorel (BD);</li>\n      <li>Clotinil (TW);</li>\n      <li>Clotiz (PH);</li>\n      <li>Clovex (JO);</li>\n      <li>Clovix (MY);</li>\n      <li>Clovixx (TW);</li>\n      <li>Copalex (HK);</li>\n      <li>Copedina (VN);</li>\n      <li>Copegrel (VN);</li>\n      <li>Cotol (TW);</li>\n      <li>CPG (ID);</li>\n      <li>Curovix (KR);</li>\n      <li>Deplat (TW);</li>\n      <li>Deplatt (ET, SG, ZW);</li>\n      <li>Deviplat (MX);</li>\n      <li>Dogrel (BD);</li>\n      <li>Duopidogrel (MY);</li>\n      <li>Egitromb (BG, VN);</li>\n      <li>G Plus (SG);</li>\n      <li>Grepid (ES, HR, IE, MT, TR);</li>\n      <li>Gridokline (MY);</li>\n      <li>Hemaflow (PH);</li>\n      <li>Hogel (CO);</li>\n      <li>Insigrel (ID);</li>\n      <li>Iscover (AR, AT, AU, BE, BG, BR, CH, CZ, DE, DK, EE, ES, FR, GB, GR, HR, HU, IE, IT, LT, MT, NL, NO, PL, PT, RO, RU, SE, SK, TR);</li>\n      <li>Kogrel (MY);</li>\n      <li>Kovix (KR);</li>\n      <li>Lopirel (HK, UA);</li>\n      <li>Maxgrel (KR);</li>\n      <li>Nabratin (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Nafamedil (VN);</li>\n      <li>Noclot (PK);</li>\n      <li>Nogrel (PH);</li>\n      <li>Noklot (ET, PH);</li>\n      <li>Panagrel (PE);</li>\n      <li>Pedovex (AE, QA);</li>\n      <li>Piax (AU, NZ);</li>\n      <li>Pidogul (KR);</li>\n      <li>Plabic (KR);</li>\n      <li>Placta (ID, SG);</li>\n      <li>Pladogrel (ID);</li>\n      <li>Plagril (SG);</li>\n      <li>Plahasan (VN);</li>\n      <li>Plahryl (UA);</li>\n      <li>Plamed (KR);</li>\n      <li>Planor (TR);</li>\n      <li>PlaquEx (BG);</li>\n      <li>Platarex (HU);</li>\n      <li>Platless (SG);</li>\n      <li>Platogrix (ID);</li>\n      <li>Platohril (UA);</li>\n      <li>Plator (BD);</li>\n      <li>Platout (TW);</li>\n      <li>Plavitor (KR);</li>\n      <li>Plavix (AE, AR, AT, AU, BB, BD, BE, BF, BG, BH, BJ, BM, BO, BR, BS, BZ, CH, CI, CL, CN, CO, CR, CU, CY, CZ, DE, DK, DO, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, GT, GY, HK, HN, HR, HU, ID, IE, IL, IS, IT, JM, JO, JP, KE, KR, KW, LB, LK, LR, LT, LU, LV, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NI, NL, NO, NZ, PA, PE, PH, PK, PL, PR, PT, PY, QA, RO, RU, SA, SC, SD, SE, SG, SI, SK, SL, SN, SR, SV, TH, TN, TR, TT, TW, TZ, UA, UG, UY, VE, VN, ZA, ZM, ZW);</li>\n      <li>Plavos (ID);</li>\n      <li>Plazep (UA);</li>\n      <li>Preto (KR);</li>\n      <li>Provic (KR);</li>\n      <li>Q.O.L. (KR);</li>\n      <li>Ravalgen (EC);</li>\n      <li>Shinclop (VN);</li>\n      <li>Simclovix (ID);</li>\n      <li>Stenvix (JO);</li>\n      <li>Talcom (CN);</li>\n      <li>Therodel (ID);</li>\n      <li>Troken (LB, MY);</li>\n      <li>Trombex (SK);</li>\n      <li>Vaclo (ID);</li>\n      <li>Vicafidt (MX);</li>\n      <li>Vivelon (PH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abraham NS, Hlatky MA, Antman EM, et al, &ldquo;ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents,&rdquo; <i>Circulation</i>, 2010, 122(24):2619-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/21060077/pubmed\" target=\"_blank\" id=\"21060077\">21060077</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson JL, Adams CD, Antman EM, et al, &quot;ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration With the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine,&quot; <i>J Am Coll Cardiol</i>, 2007, 50(7):1-157.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/17692738/pubmed\" target=\"_blank\" id=\"17692738\">17692738</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al, &quot;Contribution of Gene Sequence Variations of the Hepatic Cytochrome P450 3A4 Enzyme to Variability in Individual Responsiveness to Clopidogrel,&quot; <i>Arterioscler Thromb Vasc Biol</i>, 2006, 26(8):1895-900.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/16645157/pubmed\" target=\"_blank\" id=\"16645157\">16645157</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Angiolillo DJ, Gibson CM, Cheng S, et al, &ldquo;Differential Effects of Omeprazole and Pantoprazole on the Pharmacodynamics and Pharmacokinetics of Clopidogrel in Healthy Subjects: Randomized, Placebo-Controlled, Crossover Comparison Studies,&rdquo; <i>Clin Pharmacol Ther</i>, 2011, 89(1):65-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/20844485/pubmed\" target=\"_blank\" id=\"20844485\">20844485</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Antman EM, Anbe DT, Armstrong PW, et al, &quot;ACC/AHA 2007 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction),&quot; <i>J Am Coll Cardiol</i>, 2004, 44(3):671-719.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/15358045/pubmed\" target=\"_blank\" id=\"15358045\">15358045</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bauer ME, Bauer ST, Rabbani AB, et al, &quot;Peripartum Management of Dual Antiplatelet Therapy and Neuraxial Labor Analgesia After Bare Metal Stent Insertion for Acute Myocardial Infarction,&quot; <i>Anesth Analg</i>, 2012, 115(3):613-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/22584549/pubmed\" target=\"_blank\" id=\"22584549\">22584549</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Becker RC, Meade TW, Berger PB, et al, &quot;The Primary and Secondary Prevention of Coronary Artery Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition),&quot; <i>Chest</i>, 2008, 133(6 Suppl):776-814.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/18574278/pubmed\" target=\"_blank\" id=\"18574278\">18574278</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Clarke TA and Waskell LA, &quot;The Metabolism of Clopidogrel Is Catalyzed by Human Cytochrome P450 3A and Is Inhibited by Atorvastatin,&quot; <i>Drug Metab Dispos</i>, 2003, 31(1):53-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/12485953/pubmed\" target=\"_blank\" id=\"12485953\">12485953</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    CURRENT-OASIS 7 Investigators, Mehta SR, Bassand JP, et al, &quot;Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes,&quot; <i>N Engl J Med</i>, 2010, 363(10):930-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/20818903/pubmed\" target=\"_blank\" id=\"20818903\">20818903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    De Santis M, De Luca C, Mappa I, et al, &quot;Clopidogrel Treatment During Pregnancy: A Case Report and a Review of Literature,&quot; <i>Intern Med</i>, 2011, 50(16):1769-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/21841343/pubmed\" target=\"_blank\" id=\"21841343\">21841343</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Douketis JD, Berger PB, Dunn AS, et al, &quot;The Perioperative Management of Antithrombotic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition),&quot; <i>Chest</i>, 2008, 133(6 Suppl):299-339.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/18574269/pubmed\" target=\"_blank\" id=\"18574269\">18574269</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Finkelstein Y, Nurmohamed L, Avner M, et al, &quot;Clopidogrel Use in Children,&quot; <i>J Pediatr</i>, 2005, 147(5):657.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/16291359/pubmed\" target=\"_blank\" id=\"16291359\">16291359</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fraker TD, Fihn SD, Gibbons RJ, et al, &quot;2007 Chronic Angina Focused Update of the ACC/AHA 2002 Guidelines for the Management of Patients With Chronic Stable Angina: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to Develop the Focused Update of the 2002 Guidelines for the Management of Patients With Chronic Stable Angina,&quot; <i>Circulation</i>, 2007, 116(23):2762-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/17998462/pubmed\" target=\"_blank\" id=\"17998462\">17998462</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frelinger AL 3rd, Lee RD, Mulford DJ, et al, &quot;A Randomized, 2-Period, Crossover Design Study to Assess the Effects of Dexlansoprazole, Lansoprazole, Esomeprazole, and Omeprazole on the Steady-State Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Volunteers,&quot; <i>J Am Coll Cardiol</i>, 2012, 59(14):1304-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/22464259/pubmed\" target=\"_blank\" id=\"22464259\">22464259</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Furie KL, Kasner SE, Adams RJ, et al, &quot;Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack: A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association,&quot; <i>Stroke</i>, 2011, 42(1):227-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/20966421/pubmed\" target=\"_blank\" id=\"20966421\">20966421</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goodman SG, Menon V, Cannon CP, et al, &quot;Acute ST-Segment Elevation Myocardial Infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition),&quot; <i>Chest</i>, 2008, 133(6 Suppl):707-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/18574277/pubmed\" target=\"_blank\" id=\"18574277\">18574277</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grines CL, Bonow RO, Casey DE, et al, &quot;AHA/ACC/SCAI/ACS/ADA Science Advisory, Prevention of Premature Discontinuation of Dual Antiplatelet Therapy in Patients With Coronary Artery Stents. A Science Advisory From the American Heart Association, American College of Cardiology, Society of Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association With Representation from the Amercian College of Physicians,&quot; <i>Circulation</i>, 2007, 115(6):813-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/17224480/pubmed\" target=\"_blank\" id=\"17224480\">17224480</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hillis LD, Smith PK, Anderson JL, et al, &ldquo;2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo; <i>Circulation</i>, 2011, 124(23):2610-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/22064600/pubmed\" target=\"_blank\" id=\"22064600\">22064600</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Holmes DR, Dehmer GJ, Kaul S, et al, &quot;ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA 'Boxed Warning.' A Report of the American College of Cardiology Foundation Task Force,&quot; <i>J Am Coll Cardiol</i>, 2010, 56(4):321-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/20585015 /pubmed\" target=\"_blank\" id=\"20585015 \">20585015 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kushner FG, Hand M, Smith SC, et al, &quot;2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&quot; <i>J Am Coll Cardiol</i>, 2009, 54(23):2205-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/19942100/pubmed\" target=\"_blank\" id=\"19942100\">19942100</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lau WC, Gurbel PA, Watkins PB, et al, &quot;Contribution of Hepatic Cytochrome P450 3A4 Metabolic Activity to the Phenomenon of Clopidogrel Resistance,&quot; <i>Circulation</i>, 2004, 109(2):166-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/14707025/pubmed\" target=\"_blank\" id=\"14707025\">14707025</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levine GN, Bates ER, Blankenship JC, et al, &quot;2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,&quot; <i>Circulation</i>, 2011, 124(23):e574-651.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/22064601/pubmed\" target=\"_blank\" id=\"22064601\">22064601</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Li JS, Yow E, Berezny KY, et al, &quot;Dosing of Clopidogrel for Platelet Inhibition in Infants and Young Children: Primary Results of the Platelet Inhibition in Children On cLOpidogrel (PICOLO) Trial,&quot; <i>Circulation</i>, 2008, 117(4):553-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/18195173/pubmed\" target=\"_blank\" id=\"18195173\">18195173</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Li XQ, Andersson TB, Ahalstr&ouml;m M, et al, &quot;Comparison of Inhibitory Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole and Rabeprazole on Human Cytochrome P450 Activities,&quot; <i>Drug Metab Dispo</i>, 2004, 32(8):821-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/15258107/pubmed\" target=\"_blank\" id=\"15258107\">15258107</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maltz LA, Gauvreau K, Connor JA, et al, &quot;Clopidogrel in a Pediatric Population: Prescribing Practice and Outcomes From a Single Center,&quot; <i>Pediatr Cardiol</i>, 2009, 30(2):99-105. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/18779990/pubmed\" target=\"_blank\" id=\"18779990\">18779990</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Myers GR, Hoffman MK, and Marshall ES, &quot;Clopidogrel Use Throughout Pregnancy in a Patient With a Drug-Eluting Coronary Stent,&quot; <i>Obstet Gynecol</i>, 2011, 118(2 Pt 2):432-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/21768844/pubmed\" target=\"_blank\" id=\"21768844\">21768844</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    NCT00396877, &ldquo;Efficacy and Safety of Clopidogrel in Neonates/Infants With Systemic to Pulmonary Artery Shunt Palliation (CLARINET),&rdquo; Unpublished data. Available at <a href=\"http://clinicaltrials.gov/ct2/show/results/NCT00396877?term=clopidogrel&amp;amp;age=0&amp;amp;rank=3&amp;amp;sect=X0125#all\" target=\"_blank\">http://clinicaltrials.gov/ct2/show/results/NCT00396877?term=clopidogrel&amp;age=0&amp;rank=3&amp;sect=X0125#all</a>.  Date accessed:  April 14, 2011 .</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O'Gara PT, Kushner FG, Ascheim DD, et al, &quot;2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&quot; <i>Circulation</i>, 2013, 127(4):e362-425.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/23256914/pubmed\" target=\"_blank\" id=\"23256914\">23256914</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ogilvie BW, Yerino P, Kazmi F, et al, &ldquo;The Proton Pump Inhibitor, Omeprazole, but not Lansoprazole or Pantoprazole, is a Metabolism-Dependent Inhibitor of CYP2C19: Implications for Coadministration With Clopidogrel,&rdquo; <i>Drug Metab Dispos</i>, 2011, 39(11):2020-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/21795468/pubmed\" target=\"_blank\" id=\"21795468\">21795468</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Price MJ, Berger PB, Teirstein PS, et al, &quot;Standard- Vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention: The GRAVITAS Randomized Trial,&quot; <i>JAMA</i>, 2011, 305(11):1097-105.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/21406646/pubmed\" target=\"_blank\" id=\"21406646\">21406646</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sabatine MS, Cannon CP, Gibson CM, et al, &quot;Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction With ST-Segment Elevation,&quot; <i>N Engl J Med</i>, 2005, 352(12):1179-89.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/15758000/pubmed\" target=\"_blank\" id=\"15758000\">15758000</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Savi P, Pereillo JM, Uzabiaga MF, et al, &quot;Identification and Biological Activity of the Active Metabolite of Clopidogrel,&quot; <i>Thromb Haemost</i>, 2000, 84(5):891-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/11127873/pubmed\" target=\"_blank\" id=\"11127873\">11127873</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scirica BM, Sabatine MS, Morrow DA, et al, &quot;The Role of Clopidogrel in Early and Sustained Arterial Patency After Fibrinolysis for ST-Segment Elevation Myocardial Infarction: The ECG CLARITY-TIMI 28 Study,&quot; <i>J Am Coll Cardiol</i>, 2006, 48(1):37-42. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/16814646/pubmed\" target=\"_blank\" id=\"16814646\">16814646</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, Writing Committee Members, et al, &quot;ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA &quot;Boxed Warning&quot;: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association,&quot; <i>Circulation</i>, 2010, 122(5):537-57.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/20585015/pubmed\" target=\"_blank\" id=\"20585015\">20585015</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Soman T, Rafay MF, Hune S, et al, &quot;The Risks and Safety of Clopidogrel in Pediatric Arterial Ischemic Stroke,&quot; <i>Stroke</i>, 2006, 37(4):1120-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/16527995/pubmed\" target=\"_blank\" id=\"16527995\">16527995</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    SPS3 Investigators, &ldquo;Effects of Clopidogrel Added to Aspirin in Patients With Recent Lacunar Stroke,&rdquo;  <i>N Engl J Med</i>, 2012, 367(9):817-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/22931315/pubmed\" target=\"_blank\" id=\"22931315\">22931315</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stanek EJ, Aubert RE, Flockhart DA, et al, &ldquo;A National Study of the Effect of Individual Proton Pump Inhibitors on Cardiovascular Outcomes in Patients Treated With Clopidogrel Following Coronary Stenting: The Clopidogrel Medco Outcomes Study,&quot; Society for Cardiovascular Angiography and Interventions 2009 Scientific Sessions, Las Vegas, NV, May 6, 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wright RS, Anderson JL, Adams CD, et al, &quot;2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline) A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&quot; <i>J Am Coll Cardiol</i>, 2011, 57(18).<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-pediatric-drug-information/abstract-text/21450428/pubmed\" target=\"_blank\" id=\"21450428\">21450428</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12984 Version 197.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F10072956\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F153626\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F50667916\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1006665\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11442270\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1006697\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F153606\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F153591\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F11566548\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F6074607\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F153622\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1006666\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F153666\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F153664\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F153611\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F153595\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F153651\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F153600\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F153623\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F153602\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F3343717\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1006703\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F153594\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F153610\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F10806355\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F153613\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F153615\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12984|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=clopidogrel-drug-information\" class=\"drug drug_general\">Clopidogrel: Drug information</a></li><li><a href=\"topic.htm?path=clopidogrel-patient-drug-information\" class=\"drug drug_patient\">Clopidogrel: Patient drug information</a></li></ul></div></div>","javascript":null}